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Context: Six-transmembrane protein of prostate 2 (STAMP2) is a counter-regulator of inflamma-
tion and insulin resistance according to findings in mice. However, there have been contradictory
reports in humans.
Objective:Weaimed to explore STAMP2 in associationwith inflammatory andmetabolic status of
human obesity.
Design, Patients, and Methods: STAMP2 gene expression was analyzed in adipose tissue samples
(171 visceral and 67 sc depots) and during human preadipocyte differentiation. Human adipocytes
were treated with macrophage-conditioned medium, TNF-, and rosiglitazone.
Results: In visceral adipose tissue, STAMP2 gene expression was significantly decreased in obese
subjects, mainly in obese subjects with type 2 diabetes. STAMP2 gene expression and proteinwere
significantly and inversely associated with obesity phenotype measures (body mass index, waist,
hip, and fat mass) and obesity-associated metabolic disturbances (systolic blood pressure and
fasting glucose). In addition, STAMP2 gene expression was positively associated with lipogenic
(FASN, ACC1, SREBP1, THRSP14, TR, and TR1), CAV1, IRS1, GLUT4, and CD206 gene expression.
In sc adipose tissue, STAMP2 gene expression was not associated with metabolic parameters. In
both fat depots, STAMP2 gene expression in stromovascular cells was significantly higher than in
mature adipocytes. STAMP2geneexpressionwas significantly increasedduring thedifferentiation
process in parallel to adipogenic genes, being increased in preadipocytes derived from lean sub-
jects. Macrophage-conditioned medium (25%) and TNF- (100 ng/ml) administration increased
whereas rosiglitazone (2 M) decreased significantly STAMP2 gene expression in human differ-
entiated adipocytes.
Conclusions: Decreased STAMP2 expression (mRNA and protein) might reflect visceral adipose
dysfunction in subjects with obesity and type 2 diabetes. (J Clin Endocrinol Metab 96: 0000–0000,
2011)
Various pathways and factors in adipose tissue suchas increased release of free fatty acids and adipo-
kines, and a proinflammatory state, have been proposed
to contribute to obesity-associated insulin resistance (1,
2). Six-transmembrane protein of prostate 2 (STAMP2;
also called TIARP and STEAP4) has been characterized
as a counter-regulator of inflammation and insulin re-
sistance inmice (3). STAMP2mRNAhas been shown to
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be highly induced by TNF- exposure (4). STAMP2/
mice displayed an insulin-resistant phenotype with el-
evated plasma glucose, insulin, and lipids, elevated
expression of proinflammatory mediators in white ad-
ipose tissue, impairment of insulin-stimulated glucose
transport in adipocytes, and reduced adiponectin ex-
pression (3). These data suggest that STAMP2 expres-
sion may be synthesized as a protective antiinflamma-
tory factor and that enhancing STAMP2 signaling
potentially could be a target for human insulin resis-
tance. In this sense, two recent in vitro studies in human
preadipocytes have shown that STAMP2 contributed to
insulin sensitivity in mature human adipocytes, increas-
ing insulin-stimulated glucose uptake (5, 6).
In humans, the STAMP2 gene is highly expressed in
adipose tissue (7). Recently, two studies have reported
opposite findings. Arner et al. (8) showed that STAMP2
gene expression was increased in obese subjects in both sc
and visceral adipose tissue in five heterogeneous cohorts
[sc adipose tissuewas studied in three cohorts (in 15 nono-
bese and 81 obese women, in seven nonobese and seven
obesemen andwomen, and in 13 obesemen andwomen),
and visceral adipose tissue was studied in two other co-
horts (in 24 nonobese and 69 obese men and women and
in 20 obese men and women)]. In this last cohort, paired
visceral and sc adipose tissue sampleswasused to compare
STAMP2 mRNA and protein between sc and visceral ad-
ipose tissue. On the other hand, decreased STAMP2 gene
expression and protein in visceral adipose tissue has also
been described in obese subjects (in a study involving only
12 subjects) (7).
Here, we aimed to investigate STAMP2 gene expres-
sion in both visceral and sc adipose tissue, in adipose tissue
fractions and during human adipocyte differentiation ac-
cording to obesity status. In addition, we also explored in
vitro the effects of inflammatory agents (TNF- andmac-
rophage conditioned medium) and a peroxisome prolif-
erator-activated receptor  (PPAR) agonist (rosiglita-
zone) on STAMP2 gene expression in human adipocytes.
Materials and Methods
STAMP2 expression in adipose tissue stromal
vascular fraction (SVF) and in isolated adipocytes
Agroup of 238 adipose tissue samples (171 visceral and 67 sc
depots), from participants, who were recruited at the Endocri-
nology Department of the Hospital Virgen de la Victoria
(Malaga, Spain) andat theEndocrinologyService of theHospital
UniversitariDr. JosepTrueta (Girona, Spain),were analyzed.All
subjects were of Caucasian origin and reported that their body
weight had been stable for at least 3 months before the study.
Liver and renal diseases were specifically excluded by biochem-
ical work-up. All subjects gave written informed consent after
the purpose of the study was explained to them.
Adipose tissue samples were obtained from sc and visceral
depots during elective surgical procedures (cholecystectomy,
surgery of abdominal hernia, and gastric by-pass surgery). Both
sc and visceral fat were obtained from the abdomen, following
standard procedures. To analyze adipose tissue gene expression,
tissues were washed, fragmented, and immediately flash-frozen
in liquid nitrogen before being stored at80 C. To perform the
isolation of adipocyte and SVF, tissueswerewashed three to four
times with PBS and suspended in an equal volume of PBS sup-
plemented with 1% penicillin/streptomycin and 0.1% collage-
nase type I prewarmed to37C.The tissuewasplaced ina shaking
water bath at 37 C with continuous agitation for 60 min and
centrifuged for 5 min at 300–500 g at room temperature. The
supernatant, containingmature adipocytes,was recollected. The
pellet was identified as the SVF cell. The adipose tissue fraction-
ation was performed from eight visceral and eight sc depots.
STAMP2 expression during human preadipocyte
differentiation
Isolated preadipocytes (Zen-Bio Inc., Research Triangle
Park, NC) were plated on T-75 cell culture flasks and cultured
at 37 C and 5% CO2 in DMEM/nutrient mix F-12 medium
(1:1, vol/vol) supplemented with 10 U/ml penicillin/strepto-
mycin, 10% fetal bovine serum (FBS), 1% HEPES, and 1%
glutamine (all from GIBCO, Invitrogen S.A, Barcelona,
Spain). One week later, the isolated and expanded human
visceral and sc preadipocytes were cultured (40,000 cells/
cm2) in 12-well plates with preadipocytes medium (Zen-Bio)
composed of DMEM/nutrient mix F-12 medium (1:1, vol/vol),
HEPES, FBS, penicillin, and streptomycin in a humidified 37 C
incubator with 5% CO2. Twenty-four hours after plating, cells
were checked for complete confluence (d 0), and differentiation
was induced using differentiation medium (Zen-Bio) composed
of preadipocytes medium, human insulin, dexamethasone, iso-
butylmethylxanthine, and PPAR agonists (rosiglitazone). After
7 d (d 7), differentiation medium was replaced with fresh adi-
pocyte medium (Zen-Bio) composed of DMEM/nutrient mix
F-12medium (1:1, vol/vol), HEPES, FBS, biotin, panthothenate,
human insulin, dexamethasone, penicillin, streptomycin, and
amphotericin. Negative control (nondifferentiated cell) was per-
formedwithpreadipocytemediumduringall differentiationpro-
cesses. TNF- (100 ng/ml) and macrophage-conditioned me-
dium (MCM, 25%) fromTHP-1 cells previously treatedwith 10
ng/ml lipopolysaccharide (LPS) (MCM LPS) was added during
both sc and visceral adipocyte differentiation. Fourteen days af-
ter the initiation of differentiation, cells appeared rounded
with large lipid droplets apparent in the cytoplasm. Cells were
then considered mature adipocytes, harvested, and stored at
80 C for RNA extraction to study STAMP2 gene expression
levels after human adipocyte differentiation. The experiment
was performed in triplicate for each sample. The differentia-
tion was monitored with the fatty acid synthase (FASN,
Hs00188012_m1; Applied Biosystems Inc., Madrid, Spain)
and adiponectin (Adipoq, Hs00605917_m1; Applied Biosys-
tems) expression.
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Effects of TNF-, MCM, and rosiglitazone on
STAMP2 gene expression
After adipocyte differentiation (at d 14), sc adipocyteswere
incubated with fresh medium (control), fresh medium con-
taining TNF- (100 ng/ml), or LPS-stimulated MCM (25%)
and rosiglitazone (2 M). After 48 h, the supernatants were
centrifuged at 400 g for 5 min, the cells were harvested, and
pellets and supernatants were stored at 80 C for RNA and
protein analysis.
To evaluate the insulin action, we measure the phosphory-
lated (Ser473) [phospho- (p)AKT to total AKT ratio and the
phosphorylated (PanTyr) insulin receptor substrate 1 (pIRS1) to
IRS1 ratio using PathScan pAkt1 (Ser473) sandwich ELISA kit,
PathScan total Akt1 sandwich ELISA kit, PathScan pIRS1
(PanTyr) sandwichELISAkit, andPathScan total IRS1 sandwich
ELISA kit (Cell Signaling Technology, Izasa SA, Barcelona,
Spain). The analysis was performed following manufacturer’s
instructions. After incubation with cell lysates, pAkt (Ser473)
protein, total Akt, pIRS1 (PanTyr), or total IRS1 was captured
by the coated antibody. After extensive washing, Akt1 and IRS1
mouse antibody was added to detect the captured pAkt1 (Ser473)
and pIRS1 (PanTyr) protein, respectively. Horseradish peroxidase
(HRP)-linked antimouse antibody was then used to recognize the
bound detection antibody. HRP substrate, 3,3=5,5=-tetramethyl-
benzidine, was added to develop color. The magnitude of absor-
bance for this developed color (450 nm) was proportional to the
quantity of pAkt1 (Ser473) or pIRS1 (PanTyr) protein.
Study of gene expression
RNAwas prepared from these samples using RNeasy Lipid
Tissue Mini Kit (QIAGEN, Valencia, CA). The integrity of
each RNA sample was checked by Agilent Bioanalyzer
(Agilent Technologies, Palo Alto, CA). Total RNA was quan-
tified by means of spectrophotometer (GeneQuant; GE
Healthcare, Piscataway NJ) reverse transcribed to cDNA us-
ing the High-Capacity cDNA Archive Kit (Applied Biosys-
tems, Darmstadt, Germany) according to the manufacturer’s
protocol.
Gene expression was assessed by real-time PCR using an ABI
Prism 7000 sequence detection system (Applied Biosystems), us-
ing TaqMan and SybrGreen technology suitable for relative ge-
netic expression quantification.
The commercially available and prevalidated TaqMan primer/
probe sets used were as follows: endogenous control PPIA
(4333763, cyclophilinA) and target genes six-transmembrane pro-
tein of prostate 2 (STAMP2 or STEAP4, Hs00226415_m1), fatty
acid synthase (FASN, Hs00188012_m1), acetyl-coenzyme A car-
boxylase  (ACC, Hs00167385_m1), Spot 14 (THRSP14,
Hs00930058_m1), sterol regulatory element-binding protein 1
(SREBP1, Hs00231674_m1), PPAR (Hs00234592_m1), fatty ac-
id-binding protein 4, adipocyte (FABP4, Hs00609791_
m1), adiponectin (ADIPOQ, Hs00605917_m1), IL-6 (IL6,
Hs00985639_m1), monocyte chemoattractant protein-1 (MCP1,
Hs00234140_m1), IL-8 (IL8, Hs00174103_m1), insulin receptor
substrate 1 (IRS1, Hs00178563_m1), solute carrier family 2
TABLE 1. Anthropometric and clinical characteristics of all participants
Nonobese subjects Obese subjects
Obese with type 2
diabetes subjects P
n 74 65 32
Sex (men/women) 31/43 17/48 7/25 0.6
Age (yr) 48.35  14.2 46.3  11.5 48.5  11.7 0.5
BMI (kg/m2) 24.9  3.1 43.2  8.4a 42.5  4.7a 0.0001
Waist (cm) 85.5  10.9 118.7  18.4a 127.5  15.3a 0.0001
Hip (cm) 97.9  8.9 125.4  19.4a 131.9  15.1a 0.0001
SBP (mm Hg) 126.8  18.2 136.7  17.9a 146.3  24.9a 0.0001
DBP (mm Hg) 76.8  10.7 80  10.3 78.5  13.3 0.2
Fasting glucose (mg/dl) 84.5  10.2 95  12.1a 147.9  64.5a,b 0.0001
HDL-cholesterol (mg/dl) 56.02  14.7 59.1  15.6 51.3  11.5 0.58
LDL-cholesterol (mg/dl) 121.2  29.2 119.25  32.2 105.2  34.3 0.09
Fasting triglycerides (mg/dl) 103.25  45.5 129.3  74.3 161.6  117.5a 0.002
Gene expression in VAT (RU)
FASN 0.24 (0.12–0.35) 0.072 (0.04–0.13)a 0.04 (0.02–0.07)a 0.0001
ACC1 0.023 (0.01–0.05) 0.017 (0.01–0.03)a 0.018 (0.01–0.024)a 0.006
THRSP14 0.41 (0.26–0.6) 0.29 (0.16–0.36)a 0.19 (0.13–0.2)a 0.0001
SREBP total 0.18 (0.1–0.53) 0.11 (0.06–0.21) 0.08 (0.06–0.12) 0.5
TR 0.08 (0.04–0.13) 0.088 (0.05–0.1) 0.088 (0.04–0.1) 0.9
TR1 0.054 (0.03–0.09) 0.052 (0.03–0.067) 0.052 (0.03–0.07) 0.7
p53 0.16 (0.14–0.2) 0.17 (0.11–0.24) 0.16 (0.13–0.22) 0.4
Caveolin 1 1.37 (0.99–1.89) 1.09 (0.9–1.2)a 1.1 (0.8–1.3)a 0.005
GLUT4 0.027 (0.02–0.05) 0.017 (0.01–0.02)a 0.015 (0.009–0.019)a 0.006
IRS1 0.014 (0.008–0.02) 0.009 (0.006–0.01)a 0.008 (0.005–0.01)a 0.0001
CD68 0.105 (0.08–0.15) 0.16 (0.11–0.22)a 0.23 (0.19–0.34)a,b 0.0001
CD206 0.019 (0.012–0.03) 0.018 (0.012–0.024) 0.023 (0.017–0.03) 0.5
CD206/CD68 ratio 0.17 (0.12–0.23) 0.1 (0.07–0.13)a 0.09 (0.07–0.11)a 0.0001
STAMP2 0.35 (0.22–0.47) 0.12 (0.09–0.39)a 0.1 (0.07–0.2)a,b 0.0001
DBP, Diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; VAT, visceral adipose tissue.
a P  0.05, significant differences in obese and type 2 diabetic obese in comparison with lean subjects, by Bonferroni post hoc test.
b P  0.05, significant differences in type 2 diabetic obese in comparison with obese subjects, by Bonferroni post hoc test.
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(facilitated glucose transporter), member 4 (SLC2A4,
Hs00168966_m1), p53 (p53, Hs01034249_m1), CD68
(CD68, Hs00154355_m1), and mannose receptor, C type 1
(MRC1 or CD206, Hs00267207_m1).
The SybrGreen primer sets usedwere pre-
viously validated to give an optimal amplifi-
cationover serialdilutionsof target, andanal-
ysis ofmelting curves demonstrated a specific
single product for each gene primer. Primer
sequences were as follows: PPIA for-
ward and reverse primer sequences 5-
CAAATGCTGGACCCAACACAA-3 and
5-CCTCCACAATATTCATGCCTTCTT-
3, respectively, and CAV1 forward and
reverse primer sequences 5-AACGATGA-
CGTGGTCAAGATTG-3 and 5-TC-
CAAATGCCGTCAAAACTGT-3, respec-
tively.TR andTR1primer sequenceswere
detailed in a previous study (9).
The RT-PCRTaqMan reactionwas per-
formed in a final volume of 25l. The cycle
program consisted of an initial denaturing
of 10 min at 95 C and then 40 cycles of a
15-secdenaturingphase at 95Canda1-min
annealing and extension phase at 60 C. A
threshold cycle (Ct) value was obtained for
each amplification curve and a Ct value
was first calculated by subtracting the Ct
value for human cyclophilin A (PPIA) RNA
from the Ct value for each sample. Fold
changes compared with the endogenous
control were then determined by calculating 2Ct, so gene ex-
pression results are expressedas expression ratio relative toPPIA
gene expression according to manufacturers’ guidelines.
Western blot assays
Fat tissue was homogenized in radioimmunoprecipitation
assay buffer as we described previously (10). Protein extracts
(10 g) were loaded, resolved on 10% SDS-PAGE, and trans-
ferred to Hybond ECL nitrocellulose membranes by conven-
tional procedures. Membranes were stained with 0.15% Pon-
ceau red (Sigma-Aldrich, St. Louis,MO) to ensure equal loading
after transfer and then blocked with 5% (wt/vol) BSA in Tris-
buffered saline with 0.1% Tween 20. The primary antibodies
used were 1:4000 rabbit anti-STEAP4 (AV9842) and 1:2000
goat anti--actin (sc-1616). Blots were incubated with the ap-
propriate IgG-HRP-conjugated secondary antibody. Immuno-
reactive bands were visualized with ECL-plus reagent kit (GE
Healthcare,Uppsala, Sweden).ODof the immunoreactivebands
were measured using Image J analysis software.
Immunofluorescence
Five-micrometer sections of frozen adipose tissue were fixed
with 4% paraformaldehyde and PBS. Immunofluorescence
staining was performed overnight at 4 C with rabbit anti-
STEAP4 antibody at 1:50 dilution andmouse anti-CD68 at 1:25
dilution, washed, and visualized using Alexa Fluor 546 goat
antirabbit antibody andAlexa Fluor 488 goat antimouse (1:500;
Molecular Probes, Eugene, OR), respectively. As a negative con-
trol, the entire immunofluorescence procedurewas performed in
the absence of primary antibody. The slides were counterstained
with 4,6-diamidino-2-phenylindole to reveal nuclei and exam-
ined under a Nikon Eclipse 90i microscope.
FIG. 1. STAMP2 gene expression in visceral adipose tissue according to obesity and type 2
diabetes. CI, Confidence interval.
TABLE 2. STAMP2 gene expression in visceral adipose
tissue (n  171) in association with metabolic
parameters
r P
Age 0.04 0.6
BMI 0.47 0.0001
Waist 0.40 0.0001
Hip 0.39 0.0001
SBP 0.20 0.015
DBP 0.10 0.2
Fasting glucose 0.31 0.0001
HDL-cholesterol 0.12 0.1
LDL-cholesterol 0.21 0.01
Fasting triglycerides 0.07 0.3
Gene expression (RU)
FASN 0.24 0.006
ACC1 0.22 0.02
THRSP14 0.4 0.0001
SREBP total 0.68 0.0001
TR 0.37 0.0001
TR1 0.40 0.0001
p53 0.34 0.0001
Caveolin 1 0.25 0.005
GLUT4 0.21 0.02
IRS1 0.45 0.0001
CD68 0.15 0.09
CD206 0.36 0.0001
CD206/CD68 ratio 0.53 0.0001
DBP, Diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; RU, relative units; SBP, systolic blood pressure.
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Statistical analyses
Statistical analyses were performed using SPSS version 12.0
software. Unless otherwise stated, descriptive results of contin-
uous variables are expressed as mean and SD for Gaussian vari-
ables or median and interquartile range. Parameters that did not
fulfill normal distribution were mathematically transformed to
improve symmetry for subsequent analyses. The relation be-
tween variables was analyzed by simple correlation (Spearman’s
test) and multiple linear regression model analyses. Unpaired t
test was used to compare clinical variables and STAMP2 gene
expressions and protein levels (densitometry data) according to
obesity status and adipose tissue fractions. Unpaired t tests were
used to evaluate the effects of TNF-, MCM, and rosiglitazone
treatments on adipocytes. The experiments were performed in
triplicate. Statistical significance was set at P  0.05.
Results
STAMP2 gene expression in visceral and sc
adipose tissue
Anthropometric and clinical characteristics of all par-
ticipants are shown in Table 1. In visceral adipose tissue,
STAMP2 gene expression was significantly decreased in
obese subjects [0.11 (0.08–0.33) vs. 0.35 (0.22–0.47) rel-
ative expression, P  0.0001] (Table 1 and Fig. 1). Fur-
thermore,within the obese, STAMP2 gene expressionwas
further decreased in subjects with type 2 diabetes [0.1
(0.07–0.2) vs. 0.12 (0.09–0.39) relative expression, P 
0.03] (Table 1 and Fig. 1). In fact, STAMP2 gene expres-
sionwas significantly associatedwithmeasurementsof the
obesity phenotype [bodymass index (BMI), waist and hip
circumference, and fat mass], and obesity-associated met-
abolic disturbances (systolic blood pressure and fasting
glucose). In addition, STAMP2 gene
expression was positively associated
with the expression of lipogenic
genes (FASN, ACC1, SREBP1,
THRSP14, TR, and TR1), caveo-
lin-1 and insulin-related pathway
genes (IRS1 and GLUT-4) gene ex-
pression (Table 2). After analyzing
several multiple linear regression
models, BMI (P 0.003) and FASN
(P  0.01), ACC1 (P  0.01),
SREBP1 (P 0.001),THRSP14 (P
0.001), TR1 (P  0.04) and IRS1
(P  0.001) gene expression contrib-
uted independently to STAMP2 gene
expression variance, after controlling
for the effects of the age and fasting
glucose.STAMP2geneexpressionwas
not associated with metabolic param-
eters in sc adipose tissue.
There is evidence indicating that
mRNA levels may not necessarily predict the translated
protein levels. In this regard, we measured STAMP2 pro-
tein in adipose tissue by Western blot. STAMP2 protein
was significantly decreased in obese subjects (Fig. 2A).
STAMP2 gene expression tended to be higher in vis-
ceral adipose tissue [0.24 (0.1–0.39) vs. 0.12 (0.096–
0.15) relative gene expression, P  0.1], and in fact,
STAMP2 protein levels were significantly increased in vis-
ceral adipose tissue (Fig. 2B).
We also analyzed STAMP2 gene expression in stromo-
vascular cells (SVC) andmature adipocytes. In both visceral
and sc adipose tissue, STAMP2 gene expression in SVCwas
significantly higher than inmature adipocytes (2.5- and 7.2-
foldhigher,P0.02andP0.001, respectively) (Fig. 3). In
addition, STAMP2 gene expression in visceral adipose tis-
sue-derivedSVCtendedtobenegativelyassociatedwith fast-
ing glucose. We also tested CD14 and CD68 (two macro-
phage markers) gene expression in both fractions and
confirmed thatCD14andCD68aremore expressed inSVC.
Immunostaining analyses were performed to determine the
cellular distribution of STAMP2 protein in biopsies of adi-
pose tissue. Confirming STAMP2mRNAdata, immunoflu-
orescence detection showed a bright staining patternmainly
in the SVF cells. This staining is shown in the cytoplasm as
well as in the nuclei of a few cells. To determinewhether the
stained cellsweremacrophages, costaining analysiswas per-
formed using STAMP2 and CD68 antibodies (Fig. 4).
Finally, to investigate the relationship between STAMP2
and macrophage markers, we investigated CD68 and
CD206 [a specific marker of alternative macrophage (M2)]
gene expression in adipose tissue. STAMP2 gene expression
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FIG. 2. A, STAMP2 protein levels in visceral adipose tissue comparing nonobese vs. obese
subjects; B, comparison of STAMP2 protein levels between sc adipose tissue [SAT (S)] and
visceral adipose tissue [VAT (V)].
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was significantly associatedwithCD68 (r0.29;P0.03)
gene expression only in nonobese. However, STAMP2 gene
expression was significantly associated with CD206 gene
expression in all subjects [nonobese (r 0.46; P 0.0001),
obese (r0.54;P0.0001),andobesewith type2diabetes
(r0.49;P0.04)] andwith the ratio ofCD206 toCD68
[nonobese (r  0.32; P  0.01), obese (r  0.48; P 
0.002), and obese with type 2 diabetes (r  0.48; P 
0.045)] (Table 2).
STAMP2 gene expression during differentiation of
human preadipocytes
In isolated preadipocytes from lean and obese subjects,
STAMP2 gene expressionwas significantly increased dur-
ing the differentiation process in parallel to adipogenic
genes (Fig. 5A). STAMP2 gene expression was positively
associatedwithFASN (r0.87;P0.0001),FABP4 (r
0.83; P  0.0001), PPAR (r  0.92; P  0.0001), and
adiponectin(Adipoq) (r0.84;P0.0001)geneexpression
and negatively with IL6 (r  0.89; P  0.0001) gene
expression.
STAMP2 (Fig. 5B), FASN, ACC1, PPAR, Adipoq, and
FABP4 gene expression in lean subject-derived cells (prea-
dipocytesandadipocytes)were increased
in comparison with obese subject-de-
rivedcells.Onthecontrary, in thisgroup,
IL6 gene expression was higher in adi-
pose tissue-derived cells from obese vs.
lean subjects.
Effects of TNF-, LPS-induced
MCM, and rosiglitazone on
STAMP2 gene expression on
human adipocytes and during
adipocyte differentiation
To gain insight in themodulator fac-
tors of STAMP2 gene expression in hu-
man adipocytes, we performed the fol-
lowing treatments: TNF- (100 ng/ml),
MCM(25%), and rosiglitazone (2M).
TNF- administration increased signif-
icantly inflammatory gene expression
(IL6, IL8, and MCP1), reduced the
pIRS to IRS ratio, and did not affect
adipogenic genes. MCM administra-
tion also increased inflammatory gene
expression (IL6, IL8, and MCP1), de-
creased adipogenic gene expression
(PPAR, FASN, Adipoq, and FABP4),
and reduced pAKT to AKT ratio and
total IRS1 levels. Rosiglitazone ad-
ministration reduced inflammatory
gene expression (IL6, IL8, and
MCP1) and increased the gene expression of some adi-
pokines (Adipoq, FABP4) and pAKT to AKT and pIRS1
to IRS1 ratio (Supplemental Fig. 1, published on The
Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org).
In parallel with these data, TNF- (100 ng/ml) and
MCM (25%) administration increased significantly
STAMP2 gene expression in human adipocytes. On the
contrary, rosiglitazone (2 M) administration decreased
significantly STAMP2 gene expression (Fig. 6A).
Finally, the effects ofTNF- andLPS-inducedMCMwas
evaluated during sc and visceral adipocyte differentiation.
TNF- (100 ng/ml) and MCM (25%) administration po-
tentiated the increase of STAMP2 gene expression during
adipocyte differentiation (Fig. 6B). As expected, these treat-
ments decreased significantly adipogenic gene expression
(FASN, PPAR, and Adipoq) and led to increased the ex-
pression of the IL6 gene (Supplemental Fig. 2).
Discussion
STAMP2 is essential for prevention of excessive inflam-
mation and protection of adipocyte insulin sensitivity and
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systemic glucose homeostasis. Therefore, STAMP2 defi-
ciency is sufficient to spontaneously recapitulate many
features of the metabolic syndrome including inflamma-
tion, insulin resistance, glucose intolerance, hyperglyce-
mia, dyslipidemia, and fatty infiltration of liver and can
markedly exacerbate the metabolic abnormalities of the
ob/ob model of severe obesity (3, 5, 6). In agreement with
thesepreviousstudies,herewefoundthat
STAMP2 gene expression in visceral ad-
ipose tissue might reflect adipose tissue
dysfunction.
The main findings of the present
study are as follows.
1) This is the first study in humans,
to our knowledge, describing a direct
association of STAMP2 gene expres-
sionwith lipogenic genes suchasFASN,
ACC1, THRSP14, SREBP1, thyroid
hormone receptors (TR and TR1),
andcaveolin-1 (CAV1).The expression
of lipogenic genes (such as FASN and
ACC1) in visceral adipose tissue has
been consistently found to be decreased
in subjects with obesity and insulin re-
sistance (11). STAMP2 gene expression
followed the same expression pattern
that lipogenic genes in visceral adipose
tissue, decreased in subjects with obesity and type 2 diabe-
tes and increasing during adipocyte differentiation. In addi-
tion, we found that STAMP2 gene expression in visceral ad-
ipose tissuewas also associatedwithCAV1 gene expression.
CAV1 knockdown adipocytes displayed reductions in insu-
lin-stimulated glucose transport, insulin-triggered glucose
transporter 4 (GLUT4) recruitment to the cell surface, and
insulin receptor activation (12). Thus,
CAV1mightmodulate insulin action in
adipocytes, and the direct association
between CAV1 and STAMP2 suggests
that these two genes have an important
role in insulin action in adipose tissue.
In fact, two other insulin signaling
pathway-related genes (IRS1 and
GLUT4) were significantly associated
with STAMP2 gene expression. An-
other interesting associationwas the in-
verse relationship between p53 and
STAMP2 gene expression in visceral
adipose tissue. Recently, Minamino et
al. (13) have reported that p53 gene ex-
pression in adipose tissue promotes in-
flammation and insulin resistance in
mice.
The inverse association between
STAMP2 gene expression and obesity-
associated metabolic disturbances was
mainly found in visceral adipose tissue.
Abdominal obesity is a well-known
contributor to insulin resistance, attrib-
uted in part to the concomitant in-
FIG. 4. Immunofluorescence detection of STAMP2 and CD68 in human adipose tissue
cryosections Costaining of adipose tissue macrophages in crown-like structures surrounding
an individual adipocyte demonstrates colocalization of both proteins STAMP2 (red) and CD68
(green). The counterstaining of nuclei [4,6-diamidino-2-phenylindole (DAPI)] is shown in blue.
A, Using a 10 objective; B, using a 20 objective. Images are representative of adipose
tissue preparations collected from five subjects. The short arrows indicate STAMP2 in
macrophages (CD68	 cells), and long arrows indicate STAMP2 in the nuclei.
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creases in the circulating concentration of free fatty acids
(14, 15). In fact, lipogenic gene expression was associated
negatively with metabolic parameters only in visceral ad-
ipose tissue (11). In parallel to lipogenic genes, IRS1 and
GLUT4 gene expression in the same fat depot was signif-
icantly decreased in association with obesity.
2) In visceral adipose tissue, STAMP2 gene expression
was significantly decreased in obese subjects, mainly in
obese subjectswith type 2 diabetes. STAMP2 gene expres-
sion andproteinwas significantly and inversely associated
with obesity phenotype measures and obesity-associated
metabolic disturbances (systolic blood pressure and fast-
ing glucose). In addition, STAMP2 gene expression was
significantly decreased not only in whole adipose tissue
but also in isolated adipocytes from obese subjects.
These findings are in agreement with other studies in
humans andmice (6, 7).However,Arner et al. (8) reported
in a heterogeneous study involving five cohorts that
STAMP2 gene expressionwas increased in obese subjects.
They also reported that the STAMP2 gene was also more
expressed in sc than in visceral adipose tissue in 20 paired
samples. Differences in study design or in the character-
istics of the populations evaluated (age and cardiovascular
risk factors) may contribute to explain the differences
found.
3) The predominant STAMP2 gene expression was
found in SVC (including monocytes, preadipocytes, and
endothelial cells) in comparison with mature adipocytes.
Interestingly, monocytes express high levels of STAMP2
thatwere inversely associatedwith obesity-associated car-
diovascular alterations (16). There is previous evidence
that circulating monocytes in obese subjects are in a pro-
inflammatory state, with an increase in nuclear factor-B
transcriptional activity (17) and reduced insulin receptor
phosphorylation (18). Previous studies have demon-
strated that adipose tissue macrophages derive from cir-
culatingmonocytes, whichmigrate into the adipose tissue
under the influence of chemokines (19). These infiltrated
macrophages in visceral adipose tissue contribute to the
overall inflammatory state and interference with insulin
signal transduction (19). Thus, the relatively increased ex-
pression of STAMP2 in SVC when compared with adi-
pocytesmay be explained by the presence ofmacrophages
in adipose tissue, and this was confirmedwith the study of
the macrophage markers CD14 and CD68. Here,
STAMP2 gene expression was associated not only with
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CD68 but also robustly with CD206 gene expression in
visceral adipose tissue. CD206 is a marker of alternative
activated macrophages (M2), which are characterized to
display antiinflammatory activities. Recently, it has been
shown in mice and humans that CD206	macrophages in
adipose tissuewere directly associatedwith a healthymet-
abolic profile (20, 21). In fact, the relative levels of
CD206	 macrophages increased after gastric surgery-
inducedweight loss (22).Considering current findings,we
speculate that STAMP2 could be implicated in this anti-
inflammatory profile.
4) STAMP2 gene expression was significantly in-
creased during human adipocyte differentiation in asso-
ciation with adipogenic genes (FASN, ACC1, PPAR,
Adipoq and FABP4) and inversely associated with IL6
gene expression. These associations were in agreement
with the previous possible antiinflammatory role of
STAMP2 reported in 3T3-L1 (3). We have recently inves-
tigated the effects of an anti-inflammatory protein on
STAMP2 gene expression. Lactoferrin administration led
concomitantly tomarkedly decreased IL6 andMCP1gene
expression and to increased STAMP2 gene expression in
human adipocytes (23). In sharp contrast, Arner et al.
reported that STAMP2 gene expression decreased during
adipocyte differentiation.The lackofmethodologydetails
andof control parameters of adipocytedifferentiation (the
expression of adipogenic genes) preclude any comparison
between studies (8).
5) Here we confirmed that STAMP2 gene expression
was induced under inflammatory stimuli (TNF- and
MCM) (3, 4, 24).STAMP2gene expression increaseddur-
ing early adipocyte differentiation, with the maximum in-
crease at d 7. This increase of STAMP2mRNA levels dur-
ing adipogenesis was potentiated after inflammatory
stimuli. Thus, STAMP2 gene expression is induced after
two different stimuli (the early adipogenic program and
the inflammatory environment).
The effects of rosiglitazone (2M) leading to decreased
STAMP2 gene expression were observed in fully differen-
tiated adipocytes. In these particular cells at this stage of
differentiation, rosiglitazone did not change other genes
that are robustly induced during the early adipogenic pro-
gram (such as FASN and PPAR) but led to decreased
expression of inflammatory genes (IL6, IL8, andMCP1).
The antiinflammatory action of rosiglitazone at the cel-
lular and molecular level has been previously and first
shown by Mohanty et al. (25). However, the paradoxical
suppressive effect of rosiglitazone on STAMP2 is still un-
clear. It is possible that the inhibition of inflammatory
signals evoked by rosiglitazone results in decreased re-
quirements of STAMP2 antiinflammatory function, being
down-regulated secondarily. It is in this context of de-
creased inflammation inwhich the compensatory gene ex-
pression (STAMP2) is also lowered after rosiglitazone in
fully differentiated adipocytes.
Otherwise, IL6 gene expression was induced only by
inflammatory mediators and repressed during adipocyte
differentiation. The higher the number of differentiated
adipocytes in a given sample of adipose tissue, the higher
the STAMP2 gene expression and the lower the IL6 gene
expression. The inverse association of IL6with STAMP2
gene expression should be interpreted in this context.
In conclusion, in agreementwith the counterregulatory
properties of STAMP2 (3) in the face of nutritional (sat-
urated fatty acids) insults and its association with insulin
sensitivity, we found that reduced STAMP2 levels in vis-
ceral adipose tissue might be an important contributor to
metabolic disturbances (insulin resistance and inflamma-
tion-induced adipocyte dysfunction) in this fat depot.
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